| Literature DB >> 36072277 |
Can Feng1, Shihui Hong1, Rong Fan1, Xinjie Shi2, Zhao Ma3, Changgui Li4, Chenghao Liu5, Cong He6, Min Fan1, Ruiping Wang7,8.
Abstract
Background: An epidemic of the Omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) began in March 2022, and over 600,000 cases were confirmed until early May 2022 in Shanghai, China. Data on Omicron infections are available in other countries, but the clinical features of patients in the Chinese population, especially in Shanghai, are still lacking. We collected data from a subset of asymptomatic and mildly ill patients to learn about the age and sex disparity of Omicron infection based on changes in cycle threshold values.Entities:
Keywords: COVID-19; Omicron; RT‒PCR; SARS-CoV-2; cycle threshold; nucleic acid tests
Year: 2022 PMID: 36072277 PMCID: PMC9441582 DOI: 10.2147/JMDH.S375724
Source DB: PubMed Journal: J Multidiscip Healthc ISSN: 1178-2390
The Demographic Features of Patients with COVID-19 in a Hospital in Shanghai, China
| Variables | Total Patients (n=325) | Patients by Sex | |||
|---|---|---|---|---|---|
| Male (n=191) | Female (n=134) | ||||
| Age (years)†, mean (SD) | 47.2 (16.8) | 45.2 (16.9) | 50.1 (16.4) | −2.61 | 0.001 |
| Age (years)†, median (IQR) | 48.0 (32.5–61.0) | 45.0 (31.0–57.0) | 52.0 (38.0–64.0) | −2.84 | 0.004 |
| Age group (years)†, n (%) | 10.07 | 0.006 | |||
| <45 | 146 (44.9) | 95 (49.7) | 51 (38.1) | ||
| 45–59 | 86 (26.5) | 54 (28.3) | 32 (23.9) | ||
| ≥60 | 93 (28.6) | 42 (22.0) | 51 (38.1) | ||
| Month of hospital admission, n (%) | 1.71 | 0.191 | |||
| March | 261 (80.3) | 158 (82.7) | 103 (76.9) | ||
| April | 64 (19.7) | 33 (17.3) | 31 (23.1) | ||
| Days of hospitalization, mean (SD) | 13.6 (4.5) | 13.4 (4.3) | 13.9 (4.8) | −0.99 | 0.325 |
| Days of hospitalization, n (%) | 2.86 | 0.091 | |||
| ≤15 days | 230 (70.8) | 142 (74.3) | 88 (65.7) | ||
| >15 days | 95 (29.2) | 49 (25.7) | 46 (34.3) | ||
| Censored after hospital discharge, n (%) | 0.01 | 0.93 | |||
| Yes | 93 (28.6) | 55 (28.8) | 38 (28.4) | ||
| No | 232 (71.4) | 136 (71.2) | 96 (71.6) | ||
Note: †The differences between males and females were statistically significant (P<0.05).
Abbreviations: SD, standard deviation; IQR, interquartile range.
The Virus Nucleic Acid Detection (NAD) Tests for COVID-19 Patients in a Hospital in Shanghai, China
| Variables | Total Patients (n=325) | Patients by Sex | |||
|---|---|---|---|---|---|
| Male (n=191) | Female (n=134) | ||||
| Times of NAD test†, mean (SD) | 4.3 (2.2) | 4.1 (2.1) | 4.7 (2.4) | −2.44 | 0.015 |
| NAD test times†, n (%) | 5.39 | 0.021 | |||
| ≤5 times | 238 (73.2) | 149 (78.0) | 89 (66.4) | ||
| >5 times | 87 (26.8) | 42 (22.0) | 45 (33.6) | ||
| Duration for 1st NAD test and hospitalization, median (IQR) | 3.0 (2.0–6.0) | 5.0 (2.0–7.0) | 3.0 (2.0–6.0) | 3.79 | 0.052 |
| Ct value of virus NAD test each time, median (IQR) | |||||
| Time 1 (n=325)† | 28.4 (23.2–35.8) | 30.0 (24.3–36.6) | 27.3 (21.5–34.3) | 7.01 | 0.008 |
| Time 2 (n=325)† | 31.9 (23.8–37.2) | 33.1 (26.2–37.9) | 29.9 (21.8–35.7) | 9.70 | 0.002 |
| Time 3 (n=245) | 33.3 (26.9–37.7) | 33.7 (28.7–37.9) | 31.3 (25.6–37.2) | 2.69 | 0.101 |
| Time 4 (n=170) | 36.1 (31.0–38.7) | 36.4 (32.9–39.3) | 35.7 (30.0–38.1) | 1.96 | 0.162 |
| Time 5 (n=133) | 37.5 (34.6–40.0) | 37.7 (34.5–40.0) | 37.2 (34.9–39.4) | 0.61 | 0.435 |
| Time 6 (n=87) | 37.2 (35.6–40.0) | 37.2 (36.1–39.2) | 37.5 (35.3–40.0) | 0.02 | 0.898 |
| Time 7 (n=52) | 37.3 (36.2–39.4) | 38.1 (36.2–38.9) | 37.1 (36.1–38.7) | 1.19 | 0.275 |
| Time 8 (n=26) | 36.6 (35.1–38.9) | 36.1 (34.8–38.9) | 36.8 (35.5–38.4) | 0.29 | 0.584 |
| Time 9 (n=17) | 37.3 (36.1–38.8) | 38.3 (34.7–39.6) | 36.9 (36.1–38.3) | 0.73 | 0.393 |
| Time 10 (n=14) | 37.9 (36.4–40.0) | 37.3 (33.8–39.9) | 39.5 (37.2–40.0) | 2.25 | 0.133 |
| Time 11 (n=8) | 37.2 (36.1–39.4) | 37.1 (35.4–40.0) | 37.4 (36.7–38.8) | 0.03 | 0.881 |
| Duration between first and last NAD test†, median (IQR) | 5.0 (3.0–10.0) | 4.0 (3.0–9.0) | 6.5 (3.0–11.0) | 6.29 | 0.012 |
| Slope value for Ct changes in NAD tests, median (IQR) | 1.4 (0.5–2.2) | 1.4 (0.3–2.2) | 1.4 (0.8–2.1) | 0.17 | 0.677 |
| Proportion of slope value for Ct changes, n (%) | 0.07 | 0.796 | |||
| ≤1.5 | 184 (56.6) | 107 (56.1) | 77 (57.5) | ||
| >1.5 | 141 (43.4) | 84 (43.9) | 57 (42.5) | ||
Note: †The differences between males and females were statistically significant (P<0.05).
Abbreviations: SD, standard deviation; IQR, interquartile range; NAD, nucleic acid detection; Ct, cycle threshold.
The Influencing Factors Associated with the Slope Value for Ct Changes Based on Linear Regression for Nucleic Acid Detection (NAD) Tests Among COVID-19 Patients in Shanghai, China
| Variables | Percentage of Slope Value for Ct Changes>1.5 | Model 1 | Model 2 | ||
|---|---|---|---|---|---|
| OR | 95% CI | OR | 95% CI | ||
| Sex, n (%) | |||||
| Male | 84 (44.0) | 1.06 | 0.68–1.66 | 1.16 | 0.72–1.87 |
| Female | 57 (42.5) | Ref | Ref | ||
| Age (years), n (%) | |||||
| <45 | 73 (50.0) | ||||
| 45–59 | 40 (46.5) | ||||
| ≥60 | 28 (30.1) | Ref | Ref | ||
| Total virus NAD test times, n (%) | |||||
| ≤5 times | 108 (45.4) | 1.35 | 0.82–2.25 | 1.78 | 0.78–4.08 |
| >5 times | 33 (37.9) | Ref | Ref | ||
| Days of hospitalization, n (%) | |||||
| ≤15 days | 112 (48.7) | ||||
| >15 days | 29 (30.5) | Ref | Ref | ||
Notes: Model 1: univariate logistic regression, Model 2: multivariate logistic regression. Bold & italicized values indicate that there was a significant difference between groups.
Abbreviations: OR, odds ratio; CI, confidence interval; NAD, nucleic acid detection; Ct, cycle threshold.
Figure 1The distribution of the time interval for each nucleic acid detection (NAD) test was based on setting Time 1 (T1) as the baseline among patients of different sexes and ages with COVID-19 infection.
Figure 2Comparison of minimum, maximum, median, and mean individual cycle threshold (Ct) values among COVID-19 patients of different sexes and ages.
Figure 3The cycle threshold (Ct) value for each nucleic acid detection (NAD) test among patients of different sexes and ages with COVID-19 infection.